Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder

Psychiatry Research

Volumn 198, Issue 1, 2012, Pages 112-115

  Narasimhan, Sneha ^a   Aquino, Tiffany D ^a   Multani, Pushpinder K ^a   Rickels, Karl ^a   Lohoff, Falk W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anxiety disorders; Depression; Pharmacogenetics; Treatment response

Indexed keywords

CATECHOL METHYLTRANSFERASE; VENLAFAXINE;

ADULT; AGED; ARTICLE; COMT GENE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; GENE; GENE FREQUENCY; GENERALIZED ANXIETY DISORDER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; WESTERN HEMISPHERE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CATECHOL O-METHYLTRANSFERASE; CYCLOHEXANOLS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHARMACOGENETICS; YOUNG ADULT;

EID: 84867139177     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.12.034     Document Type: Article

References (23)

1. Andrews G., Sanderson K., Slade T., Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of the World Health Organization 2000, 78:446-454.
2. Baldwin D.S., Nair R.V. Escitalopram in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics 2005, 5:443-449.
3. Ballenger J.C. Clinical guidelines for establishing remission in patients with depression and anxiety. The Journal of Clinical Psychiatry 1999, 60:29-34.
4. Benedetti F., Colombo C., Pirovano A., Marino E., Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berlin) 2009, 203:155-160.
5. Benedetti F., Dallaspezia S., Colombo C., Lorenzi C., Pirovano A., Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. European Psychiatry 2010, 25:476-478.
6. Domschke K., Freitag C.M., Kuhlenbäumer G., Schirmacher A., Sand P., Nyhuis P., Jacob C., Fritze J., Franke P., Rietschel M., Garritsen H.S., Fimmers R., Nöthen M.M., Lesch K.P., Stögbauer F., Deckert J. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. The International Journal of Neuropsychopharmacology 2004, 7(183):188.
7. Gauderman W.J. Sample size requirements for association studies of gene-gene interaction. American Journal of Epidemiology 2002, 155:478-484.
8. Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association 2000, 283:3082-3088.
9. Hamilton S.P., Slager S.L., Heiman G.A., Deng Z., Haghighi F., Klein D.F., Hodge S.E., Weissman M.M., Fyer A.J., Knowles J.A. Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biological Psychiatry 2002, 51:591-601.
10. Hettema J.M., An S.S., Bukszar J., van den Oord E.J., Neale M.C., Kendler K.S., Chen X. Catechol-O-methyltransferase contributes to genetic susceptibility shared among anxiety spectrum phenotypes. Biological Psychiatry 2008, 64:302-310.
11. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2010, 15:473-500.
12. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., Noro M., Oswald P., Souery D., Zohar J., Massat I. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. International Clinical Psychopharmacology 2010, 25:218-227.
13. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
14. Lohoff F.W., Ferraro T.N. Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert Opinion on Pharmacotherapy 2010, 11:423-439.
15. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological Psychiatry 2009, 65:785-791.
16. Pollack M.H. Refractory generalized anxiety disorder. The Journal of Clinical Psychiatry 2009, 70(Suppl. 2):32-38.
17. Rickels K., Rynn M. Pharmacotherapy of generalized anxiety disorder. The Journal of Clinical Psychiatry 2002, 63(Suppl. 14):9-16.
18. Rickels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 1993, 50:884-895.
19. Rickels K., Rynn M., Iyengar M., Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. The Journal of Clinical Psychiatry 2006, 67:41-47.
20. Rickels K., Etemad B., Khalid-Khan S., Lohoff F.W., Rynn M.A., Gallop R.J. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Archives of General Psychiatry 2010, 67:1274-1281.
21. Szegedi A., Rujescu D., Tadic A., Müller M.J., Kohnen R., Stassen H.H., Dahmen N. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. The Pharmacogenomics Journal 2005, 5:49-53.
22. Tiwari A.K., Souza R.P., Muller D.J. Pharmacogenetics of anxiolytic drugs. Journal of Neural Transmission 2009, 116:667-677.
23. Yoshida K., Higuchi H., Takahashi H., Kamata M., Sato K., Inoue K., Suzuki T., Itoh K., Ozaki N. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Human Psychopharmacology 2008, 23:121-128.